Lv3
250 积分 2023-02-05 加入
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
13小时前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
12天前
已完结
Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer
22天前
已完结
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples Among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy In Non-Small Cell Lung Cancer
1个月前
已完结
Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial
1个月前
已完结
Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study
2个月前
已完结
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
4个月前
已完结
Small Cell Lung Cancer
5个月前
已完结
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
6个月前
已完结
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
6个月前
已完结
皖公网安备34019202002308
